RxDoctor Payments DataLook up a doctor →

Regina Pillai, MD

Pulmonary Disease · Webster, TXNPI 1720273121

Payments from drug & device makers

$403,936in general payments, 2019–2025

Across 746 payments — averaging $541.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$133K
  • GSK$120K
  • AstraZeneca$99K
  • Mylan Specialty L.p.$24K
  • Verona Pharma, Inc.$18K
  • Viiv Healthcare Company$2K
  • plus $8K from 31 others

What the payments were for

  • Consulting fees$8201%
  • Speaking & faculty fees$78,65083%
  • Travel & lodging$8511%
  • Food & beverage$13,94415%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$403,936 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$374,705
Medicare patients
357
Services billed
5,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter678$600,076
OfevNintedanib Esylate12$157,694
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr128$87,692
Breo ElliptaFluticasone/Vilanterol155$84,768
EliquisApixaban66$58,918
Spiriva RespimatTiotropium Bromide64$55,574
TezspireTezepelumab-Ekko12$46,285
SymbicortBudesonide/Formoterol Fumarate114$36,161
Albuterol Sulfate HfaAlbuterol Sulfate1,051$33,859
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$28,379
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$25,657
Advair HfaFluticasone Propion/Salmeterol55$22,308
XareltoRivaroxaban14$19,065
Combivent RespimatIpratropium/Albuterol Sulfate15$14,578
BreynaBudesonide/Formoterol Fumarate33$9,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$119,870$781,989983 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$1,538$256,224139 claims
AstraZenecaTezspire, Symbicort, Breztri Aerosphere$99,390$108,103150 claims
PfizerEliquis$307$58,91866 claims
Johnson & JohnsonXarelto$212$19,06514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →